ライフサイエンスコーパス: type 3

1 2%), followed by bla NDM (5%) and bla OXA-48-type (3%).

2 h either rapid (Type 2) or slow progression (Type 3).

3 1), 94.6% (n=193, type 2), and 99.5% (n=203, type 3).

4 chado-Joseph disease (spinocerebellar ataxia type 3).

5 he full dose (P=0.01 for the comparison with type 3).

6 iedreich's ataxia and spinocerebellar ataxia type 3.

7 rogressive familial intrahepatic cholestasis type 3.

8 us type 2, and 390 days for Sabin-like virus type 3.

9 iedreich's ataxia and spinocerebellar ataxia type 3.

10 stimulus-transducing enzyme adenylyl cyclase type 3.

11 propose to categorize as type 1, type 2, and type 3.

12 issed significance in spinocerebellar ataxia type 3.

13 ce with congenital generalized lipodystrophy type 3.

14 and mildy reduced in spinocerebellar ataxia type 3.

15 (67.0%), only 29.1% had type 1, and 3.9% had type 3.

16 73.4% for type 2 and from 39.0% to 74.1% for type 3.

17 BAergic neurons as the pathomechanism of FHM type 3.

18 rogressive familial intrahepatic cholestasis type 3.

19 maturity-onset diabetes of the young (MODY) type 3.

20 ssion or localization of glucose transporter type 3.

21 do-Joseph disease and spinocerebellar ataxia type 3.

22 0.78-0.83; type 2: 0.72; 95% CI, 0.69-0.74; type 3: 0.78; 95% CI, 0.75-0.82).

23 MacDonald-type "3 + 1" condensations with a tripyrrane, followed b

24 1), 97.6% (n=200; type 2), and 99.5% (n=204, type 3); 1/5 IPV-Al: 99.5% (n=204, type 1), 96.1% (n=197

25 use of a highly diastereoselective Mukaiyama-type [3 + 2]-annulation of allylsilane 5 with the unsatu

26 cord-like pleural tag) and prioritized into types 3, 2, and 1 when more than one type was present.

27 % decrease versus type 2) and distal AAo for type 3 (33%-39% increase versus type 2).

28 time quantitative PCR (qPCR) assays for HAdV types 3, 4, 7, 11, 14, 16, and 21 targeting the HAdV hex

29 ieve biologically important 4-O-type and 4-N-type 3,4-dihydroisocoumarin systems.

30 f TV replication in cell culture using the A type 3/4 and B saliva samples.

31 5-Hydroxytryptamine type 3 (5-HT(3)) receptors are cation-selective Cys loop

32 ariety of 5-HT receptors, including the 5-HT type-3 (5-HT3) receptors.

33 ety outcome was incidence of major bleeding (type 3-5 as per Bleeding Academic Research Consortium de

34 Bleeding Academic Research Consortium (BARC) type 3/5 bleeding was also more frequent in patients tre

35 ceptible to P. aeruginosa adhesion than wild-type (3.8-fold, 3.6-fold respectively).

36 ype 1 (63%), 8 with type 2 (47%), and 4 with type 3 (80%) achalasia after myotomy.

37 tuned regulation of glycogen synthase kinase type 3, a prime target for lithium, seems to be key.

38 fragments were evident only in patients with type 3 achalasia before treatment, intact, weak, or freq

39 One patient with type 3 achalasia had distal esophageal spasm after treat

40 onspastic achalasia and 90% of patients with type 3 achalasia/spastic esophageal motility disorders,

41 tion study in humans has recently implicated type 3 adenylyl cyclase (AC3; ADCY3) in MDD.

42 rom androstenedione through aldoketoredutase type 3 (AKR1C3) in women with insulin resistance.

43 Innate lymphoid cells (ILCs) type 3, also known as lymphoid tissue inducer cells, pla

44 e protein involved in spinocerebellar ataxia type 3, also known as Machado-Joseph disease, causes den

45 cular dystrophy type 2L and Miyoshi myopathy type 3, although the pathogenic mechanism has remained e

46 a-melanocyte-stimulating hormone (alpha-MSH) type 3 and 4 receptors, decreased LSNA in leptin-treated

47 ilt from classical dopaminergic head groups (type 3 and 4) typically elicit more balanced signaling p

48 in the setting of inherited long-QT syndrome type 3 and heart failure.

49 the identification of a higher frequency of type 3 and mixed NV and a lower frequency of type 1 NV w

50 sient local transmission of Sabin-like virus type 3 and, possibly, Sabin-like virus type 1 during per

51 Human T-cell leukemia virus types 3 and 4 (HTLV-3 and HTLV-4) are recently isolated

52 burden, time to clearance, and relapse when types 3 and 5 PDE-Is (cilostazol and sildenafil, respect

53 us to human SRD5A3 (steroid 5alpha reductase type 3) and encode polyprenol reductases responsible for

54 1), 96.1% (n=197, type 2), and 98.5% (n=202, type 3); and 1/10 IPV-Al: 98.5% (n=201, type 1), 94.6% (

55 n metapneumovirus, human parainfluenza virus type 3, and measles virus, and highly lethal emerging pa

56 as associated with a lower seroprevalence of type 3 antibodies.

57 of the B antigens, it recognizes only the A type 3 antigen among four types of A antigens tested.

58 low) expression gradient of adenylyl cyclase type 3 appears, which coincides with altered OR frequenc

59 ant of the autoimmune polyglandular syndrome type 3 (APS3v), that is defined as the co-occurrence of

60 entity autosomal recessive cerebellar ataxia type 3 (ARCA3).

61 ly denoted as autosomal-recessive cutis laxa type 3 (ARCL3).

62 ia-dependent arrhythmias in long-QT syndrome type 3 as well tachyarrhythmogenic triggers arising from

63 , myeloproliferative, and mental retardation-type 3) as a chromatin-interacting protein that promotes

64 CpG island sequences across different tissue types; 3) as only 3 or 4 bp patterns had previously been

65 Mahoney (type 1), MEF (type 2), and Saukett (type 3)-as well as for attenuated oral polio vaccines (O

66 TXN2, ATN1 and HTT in spinocerebellar ataxia type 3; ATXN1 and ATXN3 in spinocerebellar ataxia type 6

67 ion of antimuscarinic acetylcholine receptor type 3 autoantibodies.

68 ional analyses reveal that the percentage of type 3 B cells is reduced and the frequency of CD27(+) t

69 viously suggested, but also distinct anergic type 3 B cells, as well as IL-10-producing CD27(+) trans

70 at 2 years, with major bleeding defined as a type >/=3 bleed using the Bleeding Academic Research Con

71 the genes for lipoate synthase (LIAS), BolA type 3 (BOLA3), and a novel gene glutaredoxin 5 (GLRX5).

72 ic behavior in an improved competition-based type-3 BRET assay designed to circumvent such artifacts.

73 and donor eosinophil C-C chemokine receptor type 3 (CCR3) and interleukin 1 receptor-like 1 (ST2) in

74 ngenital fibrosis of the extraocular muscles type 3 (CFEOM3); 1 patient harbored a novel TUBB3 mutati

75 ding gene are associated with Usher syndrome type 3, characterized by late-onset and progressive hear

76 ed as type 1 ("dust"), type 2 ("sphere"), or type 3 ("cloud").

77 ivotal role in the transition from type 1 to type 3 collagen (Col3) synthesis and thus early tendon r

78 e/phenotype correlation for Bartter syndrome type 3: complete loss-of-function mutations associated w

79 Steroid 5alpha-reductase type 3 congenital disorder of glycosylation (SRD5A3-CDG)

80 predicted transition state for O2 binding to type 3 copper centers, providing experimental evidence f

81 Polyphenoloxidases (PPO) of the type-3 copper protein family are considered to be catech

82 n PKCalpha showed decreased expression of CR type 3 (CR3) and decreased production of TNF-alpha and I

83 Replication of strain type 3 Dearing (T3) is arrested in Madin-Darby canine ki

84 ulated intramuscularly with wild-type strain type 3 Dearing (T3D) and T3D-sigma1R202W, a point mutant

85 ine and spreads systemically, whereas strain type 3 Dearing (T3D) does not.

86 In neurons, the type 3 deiodinase (D3) inactivates thyroid hormone and r

87 Type 3 deiodinase (D3), the selenoenzyme that inactivate

88 s with high affinity to the NCAM fibronectin type-3 domain.

89 nd the second module of the NCAM fibronectin type-3 domain.

90 ch of 14 immunoglobulin-like and fibronectin type 3 domains that comprises the I-band/A-band (IA) jun

91 ch with structural similarity to fibronectin type 3 domains.

92 ult in familial hypocalciuric hypercalcaemia type 3 (FHH3), a disorder of extracellular calcium (Ca(2

93 sult in familial hypocalciuric hypercalcemia type 3 (FHH3), an extracellular calcium homeostasis diso

94 familial hemophagocytic lymphohistiocytosis type 3 (FHL3).

95 methods, we are able to show that type 1 and type 3 fimbriae are important colonization factors in th

96 Studies have shown that type 1 and type 3 fimbriae are involved in attachment and biofilm f

97 Nicotinic acetylcholine, serotonin type 3, gamma-amminobutyric acid type A, and glycine rec

98 en to mice challenged intramuscularly with M-type 3 GAS and disease course was followed for 14 days.

99 Overexpression of glucose transporter type 3 (GLUT3) in nonmalignant human breast cells activa

100 high affinity neuronal glucose transporter, type 3 (Glut3, SLC2A3).

101 ead of replication-competent, oncolytic HAdV type 3 (HAdV3).

102 Mutations causing FHM type 3 have been identified in SCN1A, the gene encoding

103 infections, 85 caused by human parechovirus type 3 (HPeV-3) and 48 by human parechovirus other than

104 Human parechoviruses (HPeVs), particularly type 3 (HPeV3), are known central nervous system (CNS) p

105 Human parainfluenza virus type 3 (hPIV-3) is a clinically significant pathogen and

106 al virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major pediatric respiratory pathogens

107 al virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major viral agents of acute pediatric

108 ovirus (hMPV), and human parainfluenza virus type 3 (hPIV3) are responsible for the majority of pedia

109 al virus (RSV) and human parainfluenza virus type 3 (HPIV3) are the first and second leading viral ag

110 al virus (RSV) and human parainfluenza virus type 3 (HPIV3) are two major causes of pediatric pneumon

111 e demonstrate that human parainfluenza virus type 3 (HPIV3) induces incomplete autophagy by blocking

112 Human parainfluenza virus type 3 (HPIV3), a paramyxovirus, is a major viral cause

113 ce glycoprotein of human parainfluenza virus type 3 (HPIV3).

114 e adaptive immune responses, but the role of type 3 IFNs in the development of primary and memory T c

115 ng IL-33 receptor), and upregulated Rorc and type 3 ILC (ILC3) genes.

116 al. (2014) now suggest an important role for type 3 ILCs (ILC3s) in the skin, particularly in psorias

117 Type 3 ILCs (ILC3s), including lymphoid tissue inducer (

118 Type 3 immunity is mediated by retinoic acid-related orp

119 optimization, 2. bulk optimization (by codon-type), 3. individualized custom (codon-by-codon) optimiz

120 No cases of WPV type 3 infection have been reported since November 2012.

121 r numbers of eosinophils and both type 2 and type 3 innate lymphoid cells (ILC2 and ILC3), specifical

122 Type 3 innate lymphoid cells (ILC3) are key players in a

123 Here, we show that type 3 innate lymphoid cells (ILC3) induced intestinal e

124 phoid organ formation depends on a subset of type 3 innate lymphoid cells (ILC3) named lymphoid tissu

125 Lymphoid organs are also home to type 3 innate lymphoid cells (ILC3), innate effector cel

126 We identified an SFB-dependent role of type 3 innate lymphoid cells (ILC3), which secreted IL-2

127 Type 3 innate lymphoid cells (ILC3s) and enteric glia, a

128 Type 3 innate lymphoid cells (ILC3s) are involved in mai

129 Type 3 innate lymphoid cells (ILC3s) are regulators of h

130 Here, we found that type 3 innate lymphoid cells (ILC3s) are severely dimini

131 Type 2 innate lymphoid cells (ILC2s) and type 3 innate lymphoid cells (ILC3s) have been implicate

132 lso associated with the expansion of CCR6(+) type 3 innate lymphoid cells (ILCs) producing IL-17A (IL

133 ate that PGE2-EP4 signaling acts directly on type 3 innate lymphoid cells (ILCs), promoting their hom

134 lial cells resulted in loss of AHR-dependent type 3 innate lymphoid cells and T helper 17 cells and i

135 Type 3 innate lymphoid cells producing predominantly GM-

136 N-gamma, IL-17A, and IL-22, all hallmarks of type 3 innate lymphoid cells, were expanded in the blood

137 ere tdTomato-C3aR(-), except some LP-derived type 3 innate lymphoid cells.

138 e, it binds, deubiquitylates, and stabilizes type 3 inositol-1,4,5-trisphosphate receptor (IP3R3), mo

139 al pigment epithelium), type 2 (subretinal), type 3 (intraretinal), and mixed neovascularization (NV)

140 ormone-inactivating (TH-inactivating) enzyme type 3 iodothyronine deiodinase (D3) is an oncofetal pro

141 d a [Ca(2+)]c signal, whereas DKO expressing type 3 IP3R (DKO3) did not.

142 We found that type 3 IS (IS3) cells that coexpress the vasoactive inte

143 Bartter syndrome type 3 is a clinically heterogeneous hereditary salt-los

144 Type 3 is associated with adaptor-related protein comple

145 rogressive familial intrahepatic cholestasis type 3 is caused by biallelic variations of ABCB4, most

146 iedreich's ataxia and spinocerebellar ataxia type 3 is not restricted to the cerebellar nuclei.

147 rdon syndrome (GS), or distal arthrogryposis type 3, is a rare, autosomal-dominant disorder character

148 The type 3 isoform of the inositol 1,4,5-trisphosphate recep

149 solated dilation of the ascending aorta; and type 3, isolated dilation of the sinus of Valsalva and/o

150 f104, inositol 1,4,5-trisphosphate receptor, type 3 (ITPR3), and discoidin domain receptor tyrosine k

151 eveloped for two viruses, MS2 and poliovirus type 3; laboratory- and field-scale experiments were con

152 tting of normal physiology, long-QT syndrome type 3-linked DeltaKPQ mutation, and heart failure.

153 trometric experiments using the intact, wild type 3-lipoyl E2p and E1p are consistent with the crysta

154 Long QT syndrome type 3 (LQT3) is a lethal disease caused by gain-of-func

155 [NaV1.5]) cause congenital long-QT syndrome type 3 (LQT3).

156 previously associated with long QT syndrome type 3 (LQTS3).

157 d HCV, presence of anti- muscarinic receptor type 3 (M3R) antibodies in SS, the role that M3R plays i

158 ta2 integrin heterodimer complement receptor type 3/Mac-1.

159 Wild-type and MC receptor type 3 (MC3)-null mice of different ages were also used.

160 e inhibits excitatory amino acid transporter type 3-mediated cysteine uptake via multiple signaling p

161 Notable among these are 23 genes encoding type 3 membrane proteins containing seven transmembrane

162 ble for maturity onset diabetes of the young type 3 (MODY3).

163 BRAF mutation, negative for KRAS mutation); type 3 (MSS or MSI low, non-CIMP, negative for BRAF muta

164 "Type 3" multilaminar fragmented hyperreflectivity (found

165 of serum anti-Ro/SSA, anti-La/SSB, and anti-type 3 muscarinic acetylcholine receptor autoantibodies

166 We previously reported that type 3 muscarinic acetylcholine receptors (M3-Rs) physic

167 years, seven female), spinocerebellar ataxia type 3 (n = 10, age range 34-67 years, three female), an

168 ffecting also CA3 and dentate gyrus (HS ILAE Type 3, n = 5) showed significantly reduced declarative

169 Two eyes were associated with a type 3 neovascularization eccentric to PEVAC.

170 nd serous) and vascularized PEDs (type 1 and type 3 neovascularization) associated with drusen and a

171 nti-VEGF therapy, and may be associated with type 3 neovascularization.

172 es as inhibitors of the Na(+)/H(+) exchanger type 3 (NHE3) are described based on a hit from high-thr

173 V-3) and 48 by human parechovirus other than type 3 (non-HPeV-3), were detected among 132 children.

174 with neurotrophic tyrosine kinase receptor, type 3 (NTRK3) and fusion of acylglycerol kinase (AGK) w

175 of the neurotrophin tyrosine kinase receptor type 3 (NTRK3) in both PAND patients and a transgenic mo

176 +OCT grading, we found a higher incidence of type 3 NV in eyes with newly diagnosed neovascular AMD t

177 MEM231 mutations in orofaciodigital syndrome type 3 (OFD3) and MKS patients that compromise transitio

178 oft tissue component at the pleural end; and type 3, one or more soft tissue cord-like pleural tag) a

179 e of a Bleeding Academic Research Consortium type 3 or 5 bleed).

180 The primary safety outcome was type 3 or 5 bleeding according to the Bleeding Academic

181 definite/probable stent thrombosis, and BARC type 3 or 5 bleeding at 12 months.

182 Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding at 12 months.

183 from inherited defects (eg, long-QT syndrome type 3 or disease-induced electric remodeling (eg, ische

184 eeding Academic Research Consortium bleeding type 3 or greater, or cardiac surgery).

185 FVIII) were investigated in 32 subjects with type 3 or severe type 1 von Willebrand disease (VWD) in

186 84), but not type 2 (OR 0.53 [0.19-1.46]) or type 3 (OR 0.56 [0.27-1.12]).

187 elets isolated from a von Willebrand disease type 3 patient with no detectable VWF, implying that she

188 A significant proportion of type 3 patients had detectable VWFpp (41%).

189 ese patients had a lower bleeding score than type 3 patients who had a complete absence of VWF:Ag and

190 mutations with rapid VWF clearance, whereas type 3 patients with no VWFpp were homozygous for null a

191 rogressive familial intrahepatic cholestasis type 3 patients.

192 rogressive familial intrahepatic cholestasis type 3 patients.

193 ad type 2 pattern in 20/38 cases (52,6%) and type 3 pattern in 18/38 cases (47,4%).

194 wed type 2 pattern in 5/38 cases (13.2%) and type 3 pattern in 33/38 cases (86,8%).

195 ressive enhancement with maximum peak in DP (type 3 pattern: severe chronic pancreatitis or PDA with

196 rogressive familial intrahepatic cholestasis type 3 (PFIC-3).

197 rogressive familial intrahepatic cholestasis type 3 (PFIC3), a rare disease that can be lethal in the

198 The unique short QT syndrome type-3 phenotype is associated with an extremely abbrevi

199 Parainfluenza virus type 3 (PIV3) infections are a major cause of morbidity

200 Parainfluenza virus type 3 (PIV3) is major pathogen of children, and no reli

201 ibit the growth of human parainfluenza virus type 3 (PIV3), a nonsegmented negative-strand RNA virus

202 Type 3 pleural tags indicated minimal increase in the li

203 Type 3 pneumococcus was the most commonly identified ser

204 o express stabilized virus-like particles of type 3 poliovirus that can induce a protective immune re

205 Proportions with seroconvsion to type 3 poliovirus were 163 (98.2%) of 166, 94.8-99.4; 17

206 Proportions to type 3 poliovirus were 166 (98.2%) of 169, 94.9-99.4; 18

207 pe 2 poliovirus, the absence of detection of type 3 poliovirus worldwide since November 2012, and cor

208 It was also shown to interact with type 3 poliovirus, albeit with about 10-fold lower affin

209 substantially decreasing the immunity gap to type 3 poliovirus.

210 ; and 90% and 89% (P=.79), respectively, for type 3 poliovirus.

211 ibody seroconversion for type 1, type 2, and type 3 polioviruses.

212 tory components of Streptococcus pneumoniae, type 3 polysaccharide and pneumolysoid (T+P), which supp

213 chado-Joseph disease (spinocerebellar ataxia type 3) (prevalence, 3.1 per 100,000 population), Friedr

214 for use with fused deposition modeling (FDM) type 3D printers.

215 alofuginone reduced collagen type 1 (but not type 3) production in injured arteries as well as that f

216 roteasome (Prosome, Macropain) subunit alpha type 3 (PSMA3) binding to p21 and protects p21 from PSMA

217 say identified that proteasome subunit alpha type 3 (Psma3) interacts with ameloblastin.

218 newly described primate T-lymphotropic virus type 3 (PTLV-3).

219 Sunlight inactivation of poliovirus type 3 (PV3), adenovirus type 2 (HAdV2), and two bacteri

220 ed chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) was developed previously as a vector e

221 transmitter receptors revealed only dopamine type 3 receptor antagonism to be significantly associate

222 risk for AMI, possibly mediated by dopamine type 3 receptor blockades.

223 s of alpha7 or the chimeric alpha7-serotonin-type 3 receptor, a feature important for preserving an a

224 or fosaprepitant, and a 5-hydroxytryptamine type 3-receptor antagonist, in patients with no previous

225 gand-gated ion channels, 5-hydroxytryptamine type 3 receptors (5-HT3Rs) are activated by the binding

226 revealed treated retinoblastoma tumor with a Type 3 regression pattern, pre- and subretinal fibrovasc

227 modified food starches with high contents of type 3 resistant starch (RS3).

228 sava starch, typically, has resistant starch type 3 (RS3) content of 2.4%.

229 Spinocerebellar ataxia type 3 (SCA3) is a neurodegenerative disorder caused by

230 e diseases, including spinocerebellar ataxia type 3 (SCA3), are caused by CAG repeat expansions that

231 neurodegeneration in Spinocerebellar Ataxia Type 3 (SCA3), one of nine inherited, incurable diseases

232 mmon dominant ataxia, spinocerebellar ataxia type 3 (SCA3).

233 sease and ataxin 3 in spinocerebellar ataxia type 3 (SCA3).

234 to a second subversion mechanism, namely the type 3 secretion (T3S) injectisome.

235 oxin macropinocytosis is independent of EHEC type 3 secretion and intimin attachment.

236 Here, we investigate the role of type 3 secretion in actin turnover occurring during toxi

237 The type 3 secretion protein PcrV and Psl exopolysaccharide

238 The type 3 secretion system (T3SS) and the bacterial flagell

239 pathogen Pseudomonas aeruginosa expresses a type 3 secretion system (T3SS) strongly associated with

240 when cytosolic receptors sense flagellin or type 3 secretion system (T3SS) structural proteins.

241 EPEC) and enterohemorrhagic E. coli employ a type 3 secretion system (T3SS) to manipulate the host in

242 is essential for the normal function of the type 3 secretion system (T3SS), for cytotoxicity toward

243 rains of Vibrio cholerae cause disease using type 3 secretion system (T3SS)-mediated mechanisms.

244 d relied on the integrity of the S. flexneri type 3 secretion system (T3SS).

245 ial proteins into host plant cells through a type 3 secretion system (T3SS).

246 ression because T6SS-1 and some effectors of type 3 secretion system 3 (T3SS-3), which is also requir

247 and its secreted RTX toxins, an intact SPI-1 Type 3 Secretion System and its effectors, hemin transpo

248 We describe a Vibrio cholerae Type 3 secretion system effector VopE that localizes to

249 The electrostatic interactions of this type 3 secretion system effector with target membranes d

250 A type 3 secretion system is used by many bacterial pathog

251 ciated with human disease and none encoded a type 3 secretion system synonymous with typical enteroha

252 attachment to enterocytes is mediated by the type 3 secretion system which functions as a molecular s

253 e, and virulence due to hyperactivity of the type 3 secretion system.

254 ct Salmonella pathogenicity island 2 (SPI-2) type 3 secretion system.

255 Type 3 secretion systems (T3SSs) of bacterial pathogens

256 are secreted into the vacuole lumen through type 3 secretion.

257 ins SipD and IpaD of Gram-negative bacterial type-3 secretion systems that breach immune barriers and

258 Type 3 seeds were composed of more than 90% necrotic mat

259 87 (90%) of 97 infants who were type-3 seronegative seroconverted after intramuscular IP

260 CI-deficient mice immunized with heat-killed type 3 serotype pneumococcus cells are impaired in gener

261 responses and succumb to challenge with live type 3 serotype pneumococcus, indicating that TACI is re

262 in motor function in patients with type 2 or type 3 SMA over a period of 24 months.

263 netically confirmed type 2 or non-ambulatory type 3 SMA.

264 me in patients with type 2 or non-ambulatory type 3 SMA.

265 Spinocerebellar ataxia type 3, spinocerebellar ataxia type 6 and Friedreich's a

266 causing severe outbreaks worldwide (sequence type 3 [ST3]), recurrent outbreaks in certain regions (e

267 Stargardt type 3 (STGD3) disease is a juvenile macular dystrophy c

268 Simian T-cell lymphotropic virus type 3 (STLV-3) is almost identical to HTLV-3.

269 In contrast, a JCPyV kidney isolate type 3 strain, WT3, has been reported to interact with s

270 In this study, we use glycoconjugates of type 3 Streptococcus pneumoniae CPS (Pn3P) to assess whe

271 ubtypes, particularly in discriminating true type 3 subjects from type 1C (reduced plasma survival of

272 of the cytoplasmic dynein light chain Tctex type 3 subunit were only observed at late Parkinson's di

273 greater homology in 2A protease sequence to type 3, suggesting that it may have been a recombinant.

274 eralocorticoid excess syndrome and Bartter's type 3 syndrome.

275 th a mononuclear Type 2 (T2) and a binuclear Type 3 (T3) site, arranged in a trinuclear copper cluste

276 In LQTS type 3, the SMR was increased between age 15 and 19 year

277 endently of gene expression (noncanonical or type 3 TR signaling).

278 that transient receptor potential canonical type 3 (TRPC3) channels are involved in hypothalamic glu

279 HR = 2.20, 95% CI: 1.47-3.31); subjects with type 3 tumors also had higher disease-specific mortality

280 tory syncytial virus and parainfluenza virus type 3, two major causes of severe respiratory tract inf

281 onfiguration was most prevalent, followed by type 3, type 2, type 5 and type 4 in that order.

282 with reporter constructs containing the wild-type 3'-UTR or when a specific anti-miR-206* inhibitor w

283 novalent, recombinant, chimpanzee adenovirus type-3 vector-based Ebola Zaire vaccine (ChAd3-EBO-Z).

284 -defective recombinant chimpanzee adenovirus type 3-vectored ebolavirus vaccine (cAd3-EBO), encoding

285 of an aerosolized human parainfluenza virus type 3-vectored vaccine that expresses the glycoprotein

286 vascular endothelial growth factor receptor type 3 (VEGFR3).

287 The atypical vesicular glutamate transporter type 3 (VGLUT3) is expressed by subpopulations of neuron

288 ombinant chimeric bovine/human parainfluenza type 3 virus (rB/HPIV3) vector expressing the respirator

289 The molecular pathology of type 3 VWD has been similarly well characterized, with a

290 nd disease (VWD), occurring in ~5% to 10% of type 3 VWD patients.

291 tients who had previously been classified as type 3 VWD.

292 WPV type 3 was isolated from only 3 persons with polio in a

293 Seroconversion for type 3 was noted in 175 infants (94%, 90-97) on bOPV sho

294 ype 1) or involving the entire AAo and arch (type 3) was found in the majority of RN-BAV patients (87

295 doses, the seroprevalences of antibodies to type 3 were 50%, 77%, and 82% after 2, 3, and 4 bOPV dos

296 V11.1, LQTS type 2), and SCN5A (NaV1.5, LQTS type 3) were performed using denaturing high-performance

297 ause maturity onset of diabetes in the young type 3, whereas murine HNF6 participates in fetal liver

298 familial hemophagocytic lymphohistiocytosis type 3 who developed AKI requiring prolonged renal repla

299 operties of type-1 (with calcium, ALA-1) and type-3 (without calcium, ALA-3) alpha-lactalbumin (ALA)

300 tations cause iron overload (hemochromatosis type 3) without overt erythroid abnormalities.